Pharmacotherapy of actinic keratosis: An update

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 13, 2012, Pages 1847-1871

  Berman, Brian ^a,b   Amini, Sadegh ^b  

^a SKIN AND CANCER ASSOCIATES   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Actinic keratosis; Chemoprevention; Field cancerization; Field directed treatment; Lesion directed treatment; Skin precancer

Indexed keywords

ALPHA TOCOPHEROL; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; AROTINOID; BETULIC ACID; CYCLOOXYGENASE 2; DEOXYRIBONUCLEASE (PYRIMIDINE DIMER); DICLOFENAC; DIMETHYL SULFONE; ETRETIN; FLUOROURACIL; HYALURONIC ACID; IMIQUIMOD; INGENOL MEBUTATE; ISOTRETINOIN; PERILLYL ALCOHOL; PHENOL; PLACEBO; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RESIQUIMOD; RETINOIC ACID; RETINOL; SALICYLIC ACID; SILYMARIN; SUNSCREEN; TRICHLOROACETIC ACID; UNINDEXED DRUG;

ACNE; ACTINIC KERATOSIS; APPLICATION SITE BURNING; APPLICATION SITE IRRITATION; APPLICATION SITE REACTION; BLISTER; CARBON DIOXIDE LASER; COLLAGEN SYNTHESIS; CONJUNCTIVITIS; CONTACT DERMATITIS; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; CURETTAGE; DECISION MAKING; DESICCATION; DNA DAMAGE; DRUG WITHDRAWAL; DRY SKIN; ERBIUM YAG LASER; ERYTHEMA; EXCISION REPAIR; EXFOLIATIVE DERMATITIS; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMIDIFIER; HYPERPIGMENTATION; HYPOPIGMENTATION; KERATINOCYTE; LASER SURGERY; LOW DRUG DOSE; LYMPHADENOPATHY; NONHUMAN; PAIN; PATIENT COMPLIANCE; PHOTODYNAMIC THERAPY; PROTECTIVE CLOTHING; PRURITUS; RADIATION EXPOSURE; REVIEW; SCAR FORMATION; SINUSITIS; SKIN ABRASION; SKIN BIOPSY; SKIN CANCER; SKIN CARCINOGENESIS; SKIN EDEMA; SKIN HYPERTROPHY; SKIN INFECTION; SKIN INFLAMMATION; SUN EXPOSURE; ULCER; ULTRAVIOLET RADIATION; XEROSIS;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; KERATINOCYTES; KERATOSIS, ACTINIC; PHOTOCHEMOTHERAPY; SKIN NEOPLASMS;

EID: 84865321445     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.716039     Document Type: Review

References (200)

1. Smit NP, Vink AA, Kolb RM, et al. Melanin offers protection against induction of cyclobutane pyrimidine dimers and 6-4 photoproducts by UVB in cultured human melanocytes. Photochem Photobiol 2001;74(3):424-30
2. Ortonne JP. Photoprotective properties of skin melanin. Br J Dermatol 2002;146(Suppl 61):7-10
3. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358(6381):15-16
4. Lookingbill DP, Lookingbill GL, Leppard B. Actinic damage and skin cancer in albinos in northern Tanzania: findings in 164 patients enrolled in an outreach skin care program. J Am Acad Dermatol 1995;32(4):653-8
5. Lehmann AR, Bridges BA. Sunlight-induced cancer: some new aspects and implications of the xeroderma pigmentosum model. Br J Dermatol 1990;122(Suppl 35):115-19 (Pubitemid 20136119)
6. Lambert WC, Kuo HR, Lambert MW. Xeroderma pigmentosum. Dermatol Clin 1995;13(1):169-209
7. Luande J, Henschke CI, Mohammed N. The Tanzanian human albino skin. Natural history. Cancer 1985;55(8):1823-8 (Pubitemid 15103932)
8. Schwartz RA. The actinic keratosis. A perspective and update. Dermatol Surg 1997;23(11):1009-19
9. Helfand M, Gorman AK, Mahon S, et al. Actinic Keratoses Final Report. U. S. Department of Health & Human Services. Available from: https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads//id1TA. pdf [Accessed 3 July 2012]
10. Memon AA, Tomenson JA, Bothwell J, et al. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000;142(6):1154-9 (Pubitemid 30418302)
11. Zagula-Mally ZW, Rosenberg EW, Kashgarian M. Frequency of skin cancer and solar keratoses in a rural southern county as determined by population sampling. Cancer 1974;34(2):345-9
12. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. J Invest Dermatol 2000;115(2):273-7 (Pubitemid 30637198)
13. Giles GG, Marks R, Foley P. Incidence of non-melanocytic skin cancer treated in Australia. Br Med J (Clin Res Ed) 1988;296(6614):13-17 (Pubitemid 18025276)
14. Marks R, Jolley D, Lectsas S, et al. The role of childhood exposure to sunlight in the development of solar keratoses and non-melanocytic skin cancer. Med J Aust 1990;152(2):62-6 (Pubitemid 20036300)
15. Kinlen LJ, Sheil AG, Peto J, et al. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979;2(6203):1461-6 (Pubitemid 10162309)
16. Blohme I, Larko O. Skin lesions in renal transplant patients after 10-23 years of immunosuppressive therapy. Acta Derm Venereol 1990;70(6):491-4 (Pubitemid 20365170)
17. Jeffes EW III, Tang EH. Actinic keratosis. Current treatment options. Am J Clin Dermatol 2000;1(3):167-79
18. Alexiades-Armenakas MR, Geronemus RG. Laser-mediated photodynamic therapy of actinic keratoses. Arch Dermatol 2003;139(10):1313-20 (Pubitemid 37248282)
19. Leffell D. New advances in treating actinic keratoses. Skin Aging 2002;10:31-2
20. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988;1(8589):795-7 (Pubitemid 18094914)
21. Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009;115(11):2523-30 Risk of progression of Aks to SCCs.
22. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000;42(1 Pt 2):23-4
23. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42(1 Pt 2):4-7
24. Guidelines for the Management of Actinic Keratoses. 2004/2005 European Dermatology Forum. Available from: http://www.euroderm.org [Accessed 02 July 2012]
25. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol 1995;32(1):95-8
26. Suchniak JM, Baer S, Goldberg LH. High rate of malignant transformation in hyperkeratotic actinic keratoses. J Am Acad Dermatol 1997;37(3 Pt 1):392-4 (Pubitemid 27430634)
27. Ehrig T, Cockerell C, Piacquadio D, et al. Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol Surg 2006;32(10):1261-5 (Pubitemid 44569998)
28. Berman B, Bienstock L, Kuritzky L, et al. Primary Care Education Consortium; Texas Academy of Family Physicians. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract 2006;55(5 Suppl):1-8
29. Quaedvlieg PJ, Tirsi E, Thissen MR, et al. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 2006;16(4):335-9 (Pubitemid 44328971)
30. Marks R, Foley P, Goodman G, et al. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986;115(6):649-55 (Pubitemid 17181888)
31. Balkrishnan R, Cayce KA, Kulkarni AS, et al. Predictors of treatment choices and associated outcomes in actinic keratoses: results from a national physician survey study. J Dermatolog Treat 2006;17(3):162-6 (Pubitemid 44147835)
32. Berman B, Villa AM, Ramirez CC. Mechanisms of action of new treatment modalities for actinic keratosis. J Drugs Dermatol 2006;5(2):167-73
33. Nora AB, Panarotto D, Lovatto L, et al. Frequency of counseling for skin cancer prevention by the various specialties in Caxias do Sul. Ann Bras Dermantol 2004;79:45-52
34. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993;329(16):1147-51 (Pubitemid 23295456)
35. Naylor MF, Boyd A, Smith DW, et al. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol 1995;131(2):170-5
36. Rigel DS. Photoprotection: a 21st century perspective. Br J Dermatol 2002;146(Suppl 61):34-7 (Pubitemid 34437809)
37. Moon TE, Levine N, Cartmel B, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997;6(11):949-56 (Pubitemid 27481644)
38. Stratton SP, Dorr RT, Alberts DS. The state-of-the-art in chemoprevention of skin cancer. Eur J Cancer 2000;36(10):1292-7 (Pubitemid 30407018)
39. Einspahr JG, Stratton SP, Bowden GT, et al. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol 2002;41(3):269-85 (Pubitemid 34203664)
40. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000;21(3):525-30 (Pubitemid 30137938)
41. Afaq F, Adhami VM, Mukhtar H. Photochemoprevention of ultraviolet B signaling and photocarcinogenesis. Mutat Res 2005;571(1-2):153-73 (Pubitemid 40313439)
42. Campbell RM, DiGiovanna JJ. Skin cancer chemoprevention with systemic retinoids: an adjunct in the management of selected high-risk patients. Dermatol Ther 2006;19(5):306-14 (Pubitemid 44470115)
43. Evans TR, Kaye SB. Retinoids: present role and future potential. Br J Cancer 1999;80(1-2):1-8 (Pubitemid 29210079)
44. Lippman SM, Lotan R. Advances in the development of retinoids as chemopreventive agents. J Nutr 2000;130(2S Suppl):479S-82S (Pubitemid 30073777)
45. Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition 2000;16(11-12):1084-9
46. Nicholson RC, Mader S, Nagpal S, et al. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO J 1990;9(13):4443-54 (Pubitemid 120026002)
47. Fanjul A, Dawson MI, Hobbs PD, et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 1994;372(6501):107- 11 (Pubitemid 24339493)
48. Pentland AP, Schoggins JW, Scott GA, et al. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999;20(10):1939-44 (Pubitemid 29476120)
49. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998;19(5):723-9 (Pubitemid 28376760)
50. Müller-Decker K, Reinerth G, Krieg P, et al. Prostaglandin-H- synthase isozyme expression in normal and neoplastic human skin. Int J Cancer 1999;82(5):648-56 (Pubitemid 29356962)
51. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999;25(4):231-40 (Pubitemid 29372908)
52. Otley CC, Stasko T, Tope WD, et al. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 2006;32(4):562-8
53. McCann PP, Bitonti AJ, Pegg AE. Inhibition of polyamine metabolism and the consequent effects on cell proliferation. In: Wattenberg L, editor. Cancer chemoprevention. CRC Press; Boca Raton, FL: 1992. p. 531-9
54. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res 1988;48(4):759-74 (Pubitemid 18061860)
55. Pegg AE, Madhubala R, Karneji T, et al. Control of ornithine decarboxylase activity in a-difluoromethylornithine-resistant L1210 cells by polyamines and synthetic analogues. J Biol Chem 1988;263(22):11008-14
56. Alberts DS, Dorr RT, Einspahr JG, et al. Chemoprevention of human actinic keratoses by topical 2-(Difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev 2000;9(12):1281-6 (Pubitemid 32044795)
57. Einspahr JG, Nelson MA, Saboda K, et al. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. Clin Cancer Res 2002;8(1):149-55 (Pubitemid 34101471)
58. Crowell PL. Prevention and therapy of cancer by dietary monoterpenes. J Nutr 1999;129(3):775S-8S
59. Belanger JT. Perillyl alcohol: applications in oncology. Altern Med Rev 1998;3(6):448-57 (Pubitemid 128709690)
60. Barthelman M, Chen W, Gensler HL, et al. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res 1998;58(4):711-16 (Pubitemid 28099482)
61. Ripple GH. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 2000;6:390-6 (Pubitemid 30111455)
62. Chaudhary SC, Alam MS, Siddiqui MS, et al. Perillyl alcohol attenuates Ras-ERK signaling to inhibit murine skin inflammation and tumorigenesis. Chem Biol Interact 2009;179(2-3):145-53
63. Stratton SP, Saboda KL, Myrdal PB, et al. Phase I study of topical perillyl alcohol cream for chemoprevention of skin cancer. Nutr Cancer 2008;60(3):325-30 (Pubitemid 351601364)
64. Stratton SP, Alberts DS, Einspahr JG, et al. A phase IIa study of topical perillyl alcohol cream for chemoprevention of skin cancer. Cancer Prev Res (Phila) 2010;3(2):160-9
65. Bozzo P, Saboda K, Einspahr JG, et al. Reliability and validity of a histologic score as a marker for skin cancer chemoprevention studies. Anal Quant Cytol Histol 2003;25(5):285-92 (Pubitemid 37280760)
66. Cafardi JA, Elmets CA. T4 endonuclease V: review and application to dermatology. Expert Opin Biol Ther 2008;8(6):829-38 (Pubitemid 351860212)
67. Yarosh D, Klein J, O'Connor A, et al. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet 2001;357(9260):926-9 (Pubitemid 32247282)
68. DeBoyes T, Kouba D, Ozog D, et al. Reduced number of actinic keratoses with topical application of DNA repair enzyme creams. J Drugs Dermatol 2010;9(12):1519-21
69. Johnson JL, Lowell BC, Ryabinina OP, et al. TAT-mediated delivery of a DNA repair enzyme to skin cells rapidly initiates repair of UV-induced DNA damage. J Invest Dermatol 2011;131(3):753-61
70. Cafardi JA, Shafi R, Athar M, et al. Prospects for skin cancer treatment and prevention: the potential contribution of an engineered virus. J Invest Dermatol 2011;131(3):559-61
71. Reagan-Shaw S, Mukhtar H, Ahmad N. Resveratrol imparts photoprotection of normal cells and enhances the efficacy of radiation therapy in cancer cells. Photochem Photobiol 2008;84(2):415-21 (Pubitemid 351421394)
72. Aziz MH, Reagan-Shaw S, Wu J, et al. Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J 2005;19(9):1193-5 (Pubitemid 40946462)
73. Baliga MS, Katiyar SK. Chemoprevention of photocarcinogenesis by selected dietary botanicals. Photochem Photobiol Sci 2006;5(2):243-53 (Pubitemid 43228052)
74. Elmets CA, Singh D, Tubesing K, et al. Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. J Am Acad Dermatol 2001;44(3):425-32 (Pubitemid 32199961)
75. Aluyen JK, Ton QN, Tran T, et al. Resveratrol: potential as anticancer agent. J Diet Suppl 2012;9(1):45-56
76. Katiyar SK, Korman NJ, Mukhtar H, et al. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 1997;89(8):556-66 (Pubitemid 27172945)
77. Katiyar SK. Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects (Review). Int J Oncol 2005;26(1):169-76
78. Katiyar SK, Meleth S, Sharma SD. Silymarin, a flavonoid from milk thistle (Silybum marianum L.), inhibits UV-induced oxidative stress through targeting infiltrating CD11b+ cells in mouse skin. Photochem Photobiol 2008;84(2):266-71 (Pubitemid 351421379)
79. Meeran SM, Katiyar S, Elmets CA, et al. Silymarin inhibits UV radiation-induced immunosuppression through augmentation of interleukin-12 in mice. Mol Cancer Ther 2006;5(7):1660-8 (Pubitemid 44323233)
80. Katiyar SK, Mantena SK, Meeran SM. Silymarin protects epidermal keratinocytes from ultraviolet radiation-induced apoptosis and DNA damage by nucleotide excision repair mechanism. PLoS One 2011;6(6):e21410
81. Fryer MJ. Evidence for the photoprotective effects of vitamin E. Photochem Photobiol 1993;58(2):304-12
82. Rhie G, Shin MH, Seo JY, et al. Aging-and photoaging-dependent changes of enzymic and nonenzymic antioxidants in the epidermis and dermis of human skin in vivo. J Invest Dermatol 2001;117(5):1212-17 (Pubitemid 34205920)
83. Gensler HL, Magdaleno M. Topical vitamin E inhibition of immunosuppression and tumorigenesis induced by ultraviolet irradiation. Nutr Cancer 1991;15(2):97-106
84. Foote JA, Ranger-Moore JR, Einspahr JG, et al. Chemoprevention of human actinic keratoses by topical DL-a-tocopherol. Cancer Prev Res (Phila Pa) 2009;2(4):394-400
85. Halpern AC, Hanson LJ. Awareness of, knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians. Int J Dermatol 2004;43(9):638-42 (Pubitemid 39276288)
86. Neidecker MV, Davis-Ajami ML, Balkrishnan R, et al. Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics 2009;27(6):451-64
87. Lubritz RR, Smolewski SA. Cryosurgery cure rates of actinic keratosis. J Am Acad Dermatol 1982;7(5):631-2 (Pubitemid 12000529)
88. Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol 2004;43(9):687-92 (Pubitemid 39276301)
89. de Berker D, McGregor JM, Hughes BR, et al. Guidelines for the management of actinic keratoses. Br J Dermatol 2007;156(2):222-30 (Pubitemid 46098882)
90. Emmett AJ, Broadbent GD. Shave excision of superficial solar skin lesions. Plast Reconstr Surg 1987;80(1):47-54 (Pubitemid 17158558)
91. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. Am Acad Dermatol 2000;42(1 Pt 2):8-10
92. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000;42(1 Pt 2):25-8
93. Fu W, Cockerell C. The Actinic (Solar) Keratosis: a 21st-Century Perspective. Arch Dermatol 2003;139(1):66-70 (Pubitemid 36091577)
94. An KP, Ratner D. Surgical management of cutaneous malignancies. Clin Dermatol 2001;19(3):305-20 (Pubitemid 32672896)
95. Geisse JK. Comparison of treatment modalities for squamous cell carcinoma. Clin Dermatol 1995;13(6):621-6 (Pubitemid 26101095)
96. David LM, Lask GP, Glassberg E, et al. Laser abrasion for cosmetic and medical treatment of facial actinic damage. Cutis 1989;43(6):583-7 (Pubitemid 19161358)
97. Iyer S, Friedli A, Bowes L, et al. Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Lasers Surg Med 2004;34(2):114-19 (Pubitemid 38326354)
98. Ostertag JU, Quaedvlieg P, Neumann M, et al. Recurrence rates and long-term follow-up after laser resurfacing as a treatment for widespread actinic keratoses in the face and on the scalp. Dermatol Surg 2006;32(2):261-7
99. Fulton JE, Rahimi AD, Helton P, et al. Disappointing results following resurfacing of facial skin with CO2 lasers for prophylaxis of keratoses and cancers. Dermatol Surg 1999;25(9):729-32 (Pubitemid 29436937)
100. Orenstein A, Goldan O, Weissman O, et al. A new modality in the treatment of actinic cheilitis using the Er:YAG laser. J Cosmet Laser Ther 2007;9(1):23-5 (Pubitemid 46581977)
101. Wollina U, Konrad H, Karamfilov T. Treatment of common warts and actinic keratoses by Er:YAG laser. J Cutan Laser Ther 2001;3(2):63-6 (Pubitemid 34112670)
102. Jiang SB, Levine VJ, Nehal KS, et al. Er: YAG laser for the treatment of actinic keratoses. Dermatol Surg 2000;26(5):437-40 (Pubitemid 30305322)
103. Coleman WP III, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg 1996;22(1):17-21; 14 (Pubitemid 26038730)
104. Harmon CB. Dermabrasion. Dermatol Clin 2001;19(3):439-42, viii (Pubitemid 32924286)
105. Fewkws JL, Cheney ML, Pollack SV. Dermabrasion. In: Fewkws JL, Cheney ML, Pollack SV, editors. Illustrated atlas of cutaneous surgery. 1st edition. J B Lippincott Co; Philadelphia, PA: 1992. p. 26.1-26.11
106. Monheit GD. Medium-depth chemical peels. Dermatol Clin 2001;19(3):413-25; vii (Pubitemid 32924284)
107. Coleman WP III. Dermal peels. Dermatol Clin 2001;19(3):405-11 (Pubitemid 32924283)
108. Yamamoto Y, Uede K, Yonei N, et al. Expression of tenascin and human B-1 integrin in the skin peeled with phenol or trichloracetic acid. Aesthet Dermatol 2003;13:17-24
109. Yamamoto Y, Uede K, Ueda M, et al. Characterization of monoclonal anti-human skin basal cell antibody 3B 4-6 and its reactivity to the skin peeled with phenol or trichloracetic acid (TCA). Aesthet Dermatol 2002;12:70-6
110. Yamamoto Y, Yonei N, Kaminaka C, et al. Effects of phenol peeling on dermal endothelial cells. J Dermatol Sci 2004;35:158-61 (Pubitemid 38969040)
111. Yamamoto Y, Uede K, Otani T, et al. Different apoptotic patterns observed in tissues damaged by phenol and TCA peels. J Dermatol Sci 2006;2(Suppl):75-81
112. Stuzin JM. Phenol peeling and the history of phenol peeling. Clin Plast Surg 1998;25:1-19 (Pubitemid 28090973)
113. Kaminaka C, Yamamoto Y, Yonei N, et al. Phenol peels as a novel therapeutic approach for actinic keratosis and Bowen disease: prospective pilot trial with assessment of clinical, histologic, and immunohistochemical correlations. J Am Acad Dermatol 2009;60(4):615-25
114. Imbertson LM, Beaurline JM, Couture AM, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998;110:734-9 (Pubitemid 28194019)
115. Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999;191:10-19 (Pubitemid 29054962)
116. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200 (Pubitemid 34141451)
117. Hengge UR, Benninghoff B, Ruzicka T, et al. Topical immunomodulators- progress towards treating inflammation, infection, and cancer. Lancet Infect Dis 2001;1:189-98 (Pubitemid 33586052)
118. Kono T, Kondo S, Pastore S, et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res 1994;13:71-6 (Pubitemid 24136345)
119. Arany I, Tyring SK, Stanley MA, et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res 1999;43:55-63 (Pubitemid 29361501)
120. Clifford JL, Walch E, Yang X, et al. Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin Cancer Res 2002;8(7):2067-72 (Pubitemid 34753575)
121. Tyring S, Conant M, Marini M, et al. Imiquimod; an international update on therapeutic uses in dermatology. Int J Dermatol 2002;41(11):810-16 (Pubitemid 35422853)
122. Ooi T, Barnetson RS, Zhuang L, et al. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol 2006;154(1):72-8 (Pubitemid 43381323)
123. Schön M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003;95(15):1138-49 (Pubitemid 37045392)
124. Schön MP, Wienrich BG, Drewniok C, et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 2004;122(5):1266-76 (Pubitemid 38651103)
125. Cryns V, Yuan J. Proteases to die for. Genes Dev 1998;12(11):1551-70 (Pubitemid 28299508)
126. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002;138(11):1498-502 (Pubitemid 35315741)
127. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 2002;47(4):571-7
128. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004;50(5):714-21 (Pubitemid 38580548)
129. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004;51(4):547-55 (Pubitemid 39278073)
130. Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg 2005;9(5):209-14 (Pubitemid 44265792)
131. Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratosis: a meta-analysis of randomized controlled trials. J Am Acad Dermatol 2006;55(3):537-8 (Pubitemid 44189601)
132. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006;126(6):1251-5 (Pubitemid 43997904)
133. Stockfleth E, Christophers E, Benninghoff B, et al. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004;140(12):1542 (Pubitemid 39627459)
134. Stockfleth E, Sterry W, Carey-Yard M, et al. Multicenter, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol 2007;157(Suppl 2):41-6 (Pubitemid 350179629)
135. Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007;157(1):133-41 (Pubitemid 46934262)
136. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase III, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005;141(4):467-73 (Pubitemid 40547405)
137. Zeichner JA, Stern DW, Uliasz A, et al. Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. J Am Acad Dermatol 2009;60(1):59-62
138. Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicenter, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007;157(Suppl 2):25-31 (Pubitemid 350179626)
139. Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007;157(Suppl 2):34-40 (Pubitemid 350179628)
140. Shoimer I, Rosen N, Muhn C. Current management of actinic keratoses. Skin Therapy Lett 2010;15(5):5-7
141. An KP, Athar M, Tang X, et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 2002;76(1):73-80
142. Denkert C, Kobel M, Berger S, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001;61(1):303-8 (Pubitemid 32095731)
143. Pearlman DL. Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol 1991;25(4):665-7
144. Yentzer B, Hick J, Williams L, et al. Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch Dermatol 2009;145(2):203-5
145. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002;70(2 Suppl):22-9
146. Loven K, Stein L, Furst K, et al. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002;24(6):990-1000 (Pubitemid 34734743)
147. Price NM. The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams. J Drugs Dermatol 2007;6(8):778-81
148. Tanghetti E, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol 2007;6(2):144-7
149. Stockfleth E, Kerl H, Zwingers T, et al. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 2011;165(5):1101-8
150. Bollag W, Ott F. Retinoic acid: topical treatment of senile or actinic keratoses and basal cell carcinomas. Agents Actions 1970;1(4):172-5
151. Barranco VP, Olson RL, Everett MA. Response of actinic keratoses to topical vitamin A acid. Cutis 1970;6:681-5
152. Bollag W, Ott F. Vitamin A acid in benign and malignant epithelial tumours of the skin. Acta Derm Venereol Suppl (Stockh) 1975;74:163-6
153. Kurka M, Orfanos CE, Pullmann H. Vitamin A acid for the topical management of epithelial neoplasms. Combination with 5-fluorouracil. Hautarzt 1978;29(6):313-18 (Pubitemid 8360231)
154. Kleinsmith DA, Thomas L. Retinoic acid in the treatment of actinic keratoses. J Dermatol Surg Oncol 1988;14:103
155. Misiewicz J, Sendagorta E, Golebiowska A, et al. Topical treatment of multiple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: a double-blind, comparative study. J Am Acad Dermatol 1991;24(3):448-51
156. Alirezai M, Dupuy P, Amblard P, et al. Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses. J Am Acad Dermatol 1994;30(3):447-51 (Pubitemid 24129437)
157. Buggiani G, Troiano M, Rossi R, et al. Photodynamic therapy: off-label and alternative use in dermatological practice. Photodiagnosis Photodyn Ther 2008;5(2):134-8
158. Wang XL, Wang HW, Guo MX, et al. Treatment of skin cancer and pre-cancer using topical ALA-PDT-a single hospital experience. Photodiagnosis Photodyn Ther 2008;5(2):127-33
159. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002;47(2):258-62
160. Touma D, Yaar M, Whitehead S, et al. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 2004;140(1):33-40 (Pubitemid 38090268)
161. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007;56(1):125-43 (Pubitemid 44969292)
162. Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase III, multicenter trials. Arch Dermatol 2004;140(1):41-6 (Pubitemid 38090269)
163. Tierney E, Barker A, Ahdout J, et al. Photodynamic therapy for the treatment of cutaneous neoplasia, inflammatory disorders, and photoaging. Dermatol Surg 2009;35(5):725-46
164. DUSA Pharmaceuticals. Levulan kerastick (aminolevulinic acid HCL) for topical solution, 20%. Prod Insert 2004
165. Hædersdal M, Sakamoto FH, Farinelli WA, et al. Fractional CO(2) laser-assisted drug delivery. Lasers Surg Med 2010;42:113-22
166. Hædersdal M, Katnelson J, Sakamoto FH, et al. Enhanced uptake and photoactivation of topical methyl aminolevulinate after fractional CO2 laser pretreatment. Lasers Surg Med 2011;43(8):804-13
167. Togsverd-Bo K, Haak CS, Thaysen-Petersen D, et al. Intensified photodynamic therapy of actinic keratoses with fractional CO(2) laser: a randomized clinical trial. Br J Dermatol 2012;166(6):1262-9
168. Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis 2002;70(2 Suppl):30-6
169. Muston D, Downs A, Rives V. An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat 2009;20(5):266-75
170. Caekelbergh K, Annemans L, Lambert J, et al. Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br J Dermatol 2006;155(4):784-90 (Pubitemid 44352560)
171. Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003;14(2):99-106 (Pubitemid 36648700)
172. Wilson EC. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics 2010;28(11):1055-64
173. Gold MH. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J Drugs Dermatol 2008;7(1):23-5
174. Shaffelburg M. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream. J Drugs Dermatol 2009;8(1):35-9
175. Ingenol mebutate packet insert. Available from: www.FDA.org [Accessed 23 June 2012]
176. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol 2012;66(3):486-93
177. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012;366(11):1010-19
178. Stein Gold L, Larsson T, Melgaard A. Long-term Follow-up Studies of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis. Poster #5620 presented at the 70th Annual Meeting of the American Academy of Dermatology; 16-20 March 2012; San Diego, CA
179. Testerman TL, Gerster JF, Imbertson LM, et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995;58:365-72
180. Tomai MA, Gibson SJ, Imbertson LM, et al. Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res 1995;28:253-64
181. Jones T. Resiquimod 3M. Curr Opin Investig Drugs 2003;4:214-18
182. Szeimies RM, Bichel J, Ortonne JP, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol 2008;159(1):205-10 (Pubitemid 351874499)
183. Jäger S, Laszczyk MN, Scheffler A. A preliminary pharmacokinetic study of betulin, the main pentacyclic triterpene from extract of outer bark of birch (Betulae alba cortex). Molecules 2008;13(12):3224-35
184. Krasutsky PA. Birch bark research and development. Nat Prod Rep 2006;23(6):919-42 (Pubitemid 44808994)
185. Huyke C, Reuter J, Rödig M, et al. Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges 2009;7(2):128-33
186. Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratosis: an update and comparison. Dermatol Surg 2000;26(8):728-32; 4 (Pubitemid 30620516)
187. Hadley J, Tristani-Firouzi P, Hull C, et al. Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses. Dermatol Surg 2012;38(5):722-7
188. Serra-Guillén C, Nagore E, Hueso L, et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol 2012;66(4):e131-7
189. Hanke CW, Beer KR, Stockfleth E, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol 2010;62(4):573-81
190. Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010;62(4):582-90
191. Hanke CW, Swanson N, Bruce S, et al. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. J Drugs Dermatol 2011;10(2):165-70
192. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002;146(1):94-100 (Pubitemid 34158414)
193. Mastrolonardo M. Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses. Clin Exp Dermatol 2009;34(1):33-5
194. Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol 2006;5(2):156-9
195. Kose O, Koc E, Erbil AH, et al. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. J Dermatolog Treat 2008;19(3):159-63 (Pubitemid 351882995)
196. Ulrich C, Johannsen A, Röwert-Huber J, et al. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol 2010;20(4):482-8
197. Smith S, Piacquadio D, Morhenn V, et al. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2003;2(6):629-35
198. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003;48(2):227-32 (Pubitemid 36232321)
199. Tarstedt M, Rosdahl I, Berne B, et al. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 2005;85(5):424-8 (Pubitemid 41345617)
200. Sotiriou E, Apalla Z, Maliamani F, et al. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. J Eur Acad Dermatol Venereol 2009;Sep23(9):1061-5